Each line is a different country's JAK inhibitor for RA registry, looking at drug stopped for adverse events. Why all the variation? (Until we sort that out, we'll struggle to assess JAKi post-marketing safety...) @k_lauper's JAK-pot study POS0093 #EULAR2021 @RheumNow https://t.co/YykoG7LlEw

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.

#EULAR2021: In India, some of the JAKi are costing less than $30/mo per a EULAR participant! Dr. Filip van den Bosch does not recommend using tofacitinib as a diagnostic tool for SpA over NSAIDs even if it is so cheap. @RheumNow

#EULAR2021: If we review ASAS40 response from infliximab to tofacitinib, then there has not been much evolution in efficacy of therapy for SpA in the past 20 yrs. This suggests we haven't been looking at the right endpoint in measuring efficacy! MDA instead! @RheumNow https://t.co/E61yb97CRN

Novel Results from the @rheum_covid register in #RA patients presented by @jeffsparks #OP0006 Higher risk for patients on rituximab or on JAK inhibitors for hospitalisation & ventilation or death after #COVID19 infection compared to TNFi users. #EULAR2021 @RheumNow https://t.co/40h5zVpxAO

Excellent job by @jeffsparks @zach_wallace_md @rheum_covid on Abs#0P0006 at #EULAR2021. ⭐️RTX and JAKi: increased COVID severity, not seen in IL-6 or ABA. Critical findings, but confounding role of co-morbidities/ILD/cancer, esp in RTX patients? @RheumNow

Yes more lab abnormalities in #Upadactinib vs #Adalimumab in RA RCTs including cytopenias, transaminitis but not creatinine @RheumNow @eular_org #EULAR2021 but no diff in treatmt emergent Adverse events abst OP0128 Yes do labs when on #Upadacitinib https://t.co/5ypKGxuE3U https://t.co/XRjr0gDnIT

• https://twitter.com/janetbirdope/status/1400249617590194176

Do you really needs to follow labs for pts on #JAKi ? @eular_org #EULAR2021 OP0128 studied 4.5 years in #upadacitinb 6 RCTs in RA. More grade3 or 4 anemia, low lymph, neutrophils & ⬆️

To clot or NOT? Real world data usually show no ⬆️ VTE in RA with #Jaki compares to other advanced therapies. Diff from high CV risk pts in Oral Surveillance where Tofacitinib had higher VTE vs TNFi @AbbVie symposium @eular_org #EULAR2021 @RheumNow Hard to reconcile diff risk. https://t.co/AWY2zZPSIb

Andrew Ostor @AbbVie symposium @eular_org presented HZ vaccines are safe in RA pts with #JAKi but with Recombinant HZ vaccine humeral response - 75% in RA pts in JAKi vs 100% controls. So should we hold JAKi with Shringix & if so for 1 or 2 wks? #EULAR2021 @RheumNow https://t.co/wVOFMa9fLm

Lifetime risk of HZ is 30%! ⬆️ in pts with immune diseases or immunesuppression. All #JAKI ⬆️ risk maybe doubling but NNH & NNT give context. UPA Rx in active RA -20 more pts in remission vs 1 excess HZ if comparing UPA to ADA in RA @RheumNow #EULAR2021 AbbVie symposium https://t.co/14i0IsIpzs

Do you think JAKi cause VTE? @eular_org @RheumNow #EULAR2021

Do you think #JAKI ⬆️ #MACE cardiovascular events vs TNFi? @eular_org @RheumNow #EULAR2021